Clinical Trial

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 11, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B. * Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. * Complete the study procedures specified in the protocol, which is guided by researchers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-26.
Trial Details
NCT Number NCT06111274
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions Advanced Pancreatic Cancer
Enrollment 82 participants
Start Date 2023-10-17
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-12-29 (estimated)
Updated on ClinicalTrials.gov 2024-04-11